{"filing":{"accession_number":"0001104659-26-086406","cik":"0001649989","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-23","report_date":"2026-07-21","primary_document":"tm2621232d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926086406/tm2621232d1_8k.htm"},"events":[{"id":20235,"run_id":18220,"accession_number":"0001104659-26-086406","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The disclosure centers on the Compensation Committee's approval of stock option grants (100,000 options to CEO Robert C. Jahr and 210,078 options to CFO Lawrence A. Kenyon) and cash bonus opportunities ($420,000 and $200,000 respectively) contingent on FDA approval of ONS-5010. This is a classic compensatory arrangement disclosure under Item 5.02(e), involving equity grants and performance-based cash awards to named executives.","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19540,"accession_number":"0001104659-26-086406","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on the Compensation Committee's approval of stock option grants (100,000 options to CEO Robert C. Jahr and 210,078 options to CFO Lawrence A. Kenyon) and cash bonus opportunities ($420,000 and $200,000 respectively) contingent on FDA approval of ONS-5010. This is a classic compensatory arrangement disclosure under Item 5.02(e), involving equity grants and performance-based cash awards to named executives.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T10:06:03.699624+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19540,"accession_number":"0001104659-26-086406","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on the Compensation Committee's approval of stock option grants (100,000 options to CEO Robert C. Jahr and 210,078 options to CFO Lawrence A. Kenyon) and cash bonus opportunities ($420,000 and $200,000 respectively) contingent on FDA approval of ONS-5010. This is a classic compensatory arrangement disclosure under Item 5.02(e), involving equity grants and performance-based cash awards to named executives.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T10:06:03.699624+00:00","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-07-23"}]}